Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

About the ARK - Project

The overarching aim of ARK is to reduce the incidence of serious infections caused by antibiotic-resistant bacteria in the future, through substantially and safely reducing antibiotic use in hospitals now.

 

The specific research questions are:

  • how can antibiotic prescription ‘review&revise’ strategies be implemented optimally to reduce antibiotic use safely within hospitals?
  • can we build a feasible inexpensive package of interventions that increase prescriber compliance with ‘review&revise’, and patient acceptability of shorter antibiotic therapy durations driven by ‘review&revise’?
  • are ‘review&revise’ strategies cost-effective across a range of scenarios reflecting plausible associations between antibiotic use now and future resistance leading to loss of antibiotic options?

ARK_logo_small162x81.png

In this section

The Bio-medical Research Council (BRC), a part of the Oxford Hospital Radcliffe Trust (OHRT), funds research and many of our staff are involved in BRC research.

Our research is funded from a variety of funders. Their support allows our research to focus on the basic and clinical research domains to accelerate knowledge translation from the bedside to the bench, and back again.